GCgenome Posts 15.7 Billion Won in First-Half Sales... Five Consecutive Quarters of Operating Profit

Sales and Operating Profit Up 8% and 119%, Respectively... Record-High First Half Performance
Growth of ai-CANCERCH and G-NIPT... Plans to Enter U.S. Pancreatic Cancer Market

GCgenome announced on the 14th that it recorded sales of 15.72 billion won and an operating profit of 570 million won in the first half of this year. Compared to the same period last year, sales increased by 8% and operating profit surged by 119%. Net profit for the period grew to 1.6 billion won, supported by improvements in financial income and expenses.

GC Genome Company Logo Image. GC Genome

For the second quarter, sales reached 8.3 billion won and operating profit was 400 million won, representing increases of 12% and 207%, respectively, compared to the previous quarter. This marks five consecutive quarters of operating profit since the second quarter of last year.

By business segment, tests for obstetrics, cancer, and genetic rare diseases all achieved balanced growth. The strong performance was supported by major products such as the non-invasive prenatal test ‘G-NIPT’ and the multi-cancer early screening test ‘ai-CANCERCH’. As a result of improved operating activities, the company’s cash reserves also rose from approximately 40 billion won at the end of last year to 42.1 billion won at the end of the first half of this year.

GCgenome is also seeking to enter the U.S. pancreatic cancer screening market. The company is conducting sample collection and performance validation with local U.S. participants and plans to apply for designation as an FDA Breakthrough Medical Device in the future.

This content was produced with the assistance of AI translation services.